1.A Case of Placenta Increta Presenting as Delayed Postabortal Hemorrhage.
Min Joung KIM ; In KWEN ; Jen A KIM ; Soo Young HUR ; Sa Jin KIM ; Eun Joung KIM
Korean Journal of Obstetrics and Gynecology 2005;48(3):755-759
Placenta increta is a life-threatening complication of pregnancy characterized by invasion of placenta villi into the underlying myometrium. Usually, presentation is in the early postpartum period with hemorrhage during difficult placental removal. Although placenta increta may complicate first and early second-trimester pregnancy loss, this lesion is rarely found, whose diagnosis can be very difficult during these trimester. We had experienced a case of placenta increta which was found about 14 days after dilatation and curettage (D and C) due to missed abortion at private obstetrics' clinic and report this with brief reviewed the literatures.
Abortion, Missed
;
Animals
;
Diagnosis
;
Dilatation and Curettage
;
Female
;
Hemorrhage*
;
Humans
;
Mice
;
Myometrium
;
Placenta Accreta*
;
Placenta*
;
Postpartum Period
;
Pregnancy
;
Pregnancy Trimester, First
2.Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.
Joon Oh PARK ; Do Youn OH ; Chiun HSU ; Jen Shi CHEN ; Li Tzong CHEN ; Mauro ORLANDO ; Jong Seok KIM ; Ho Yeong LIM
Cancer Research and Treatment 2015;47(3):343-361
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.
Appointments and Schedules
;
Biliary Tract Neoplasms*
;
Cholangiocarcinoma
;
Cisplatin*
;
Congresses as Topic
;
Drug Therapy
;
Gallbladder Neoplasms
;
Humans
;
Incidence
;
Population Characteristics
3.A Case of Sclerosing Stromal Tumor of the Ovary.
Cheol Soo SHIN ; Jung Jun KIM ; Chang Su YUN ; Hyun Ju CHO ; Kook Howan BAE ; Kwang Su HAN ; Jung Sil PARK ; Mi Kyung JEN
Korean Journal of Obstetrics and Gynecology 2003;46(9):1818-1822
Sclerosing stromal tumor of ovary is extremely rare benign neoplasm, occurring predominently in the second and third decades of life. It was first described by Chalvardjian and Scully in 1973 and by Damjanov in 1975 as distinctive subtype of other ovarian sex cord stromal tumor. This tumor differs from the fibroma, thecoma and lipid cell tumor clinically and pathologically by showing pseudolobular pattern, prominent vascularity and cell heterogeneity. We report a case of sclerosing stromal tumor of the ovary in 30-year-old woman with brief review of the literature.
Adult
;
Female
;
Fibroma
;
Humans
;
Ovary*
;
Population Characteristics
;
Sex Cord-Gonadal Stromal Tumors
;
Thecoma
4.DSSylation, a novel protein modification targets proteins induced by oxidative stress, and facilitates their degradation in cells.
Yinghao ZHANG ; Fang-Mei CHANG ; Jianjun HUANG ; Jacob J JUNCO ; Shivani K MAFFI ; Hannah I PRIDGEN ; Gabriel CATANO ; Hong DANG ; Xiang DING ; Fuquan YANG ; Dae Joon KIM ; Thomas J SLAGA ; Rongqiao HE ; Sung-Jen WEI
Protein & Cell 2014;5(2):124-140
Timely removal of oxidatively damaged proteins is critical for cells exposed to oxidative stresses; however, cellular mechanism for clearing oxidized proteins is not clear. Our study reveals a novel type of protein modification that may play a role in targeting oxidized proteins and remove them. In this process, DSS1 (deleted in split hand/split foot 1), an evolutionally conserved small protein, is conjugated to proteins induced by oxidative stresses in vitro and in vivo, implying oxidized proteins are DSS1 clients. A subsequent ubiquitination targeting DSS1-protein adducts has been observed, suggesting the client proteins are degraded through the ubiquitin-proteasome pathway. The DSS1 attachment to its clients is evidenced to be an enzymatic process modulated by an unidentified ATPase. We name this novel protein modification as DSSylation, in which DSS1 plays as a modifier, whose attachment may render target proteins a signature leading to their subsequent ubiquitination, thereby recruits proteasome to degrade them.
Free Radicals
;
metabolism
;
HeLa Cells
;
Humans
;
Oxidation-Reduction
;
Oxidative Stress
;
genetics
;
Proteasome Endopeptidase Complex
;
genetics
;
metabolism
;
Protein Binding
;
Protein Modification, Translational
;
genetics
;
Ubiquitin
;
metabolism
;
Ubiquitination
;
genetics
5.Comparison of trauma systems in Asian countries: a cross-sectional study
Young Hee JUNG ; Dae Han WI ; Sang Do SHIN ; Hideharu TANAKA ; Goh E SHAUN ; Wen Chu CHIANG ; Jen Tang SUN ; Li Min HSU ; Kentaro KAJINO ; Sabariah Faizah JAMALUDDIN ; Akio KIMURA ; James F HOLMES ; Kyoung Jun SONG ; Young Sun RO ; Ki Jeong HONG ; Sung Woo MOON ; Ju Ok PARK ; Min Jung KIM
Clinical and Experimental Emergency Medicine 2019;6(4):321-329
OBJECTIVE: This study aimed to compare the demographic characteristics and trauma service structures and processes of hospitals in 15 countries across the Asia Pacific, and to provide baseline data for the integrated trauma database: the Pan-Asian Trauma Outcomes Study (PATOS).METHODS: Medical directors and emergency physicians at PATOS-participating hospitals in countries across the Asia Pacific were surveyed through a standardized questionnaire. General information, trauma care system data, and trauma emergency department (ED) outcomes at each hospital were collected by email and analyzed using descriptive statistics.RESULTS: Survey data from 35 hospitals across 15 countries were collected from archived data between June 2014 and July 2015. Designated trauma centers were identified as the highest hospital level for trauma patients in 70% of surveyed countries. Half of the hospitals surveyed had special teams for trauma care, and almost all prepared activation protocol documents for these teams. Most hospitals offered specialized trauma education programs, and 72.7% of hospitals had a hospital-based trauma registry. The total number of trauma patients visiting the ED across 25 of the hospitals was 300,376. The overall survival-to-discharge rate was 97.2%; however, it varied greatly between 85.1% and 99.7%. The difference between survival-to-discharge rates of moderate and severe injury groups was highest in Taiwan (41.8%) and lowest in Thailand (18.6%).CONCLUSION: Trauma care systems and ED outcomes vary widely among surveyed hospitals and countries. This information is useful to build further detailed, systematic platforms for trauma surveillance and evidence-based trauma care policies.
Asia
;
Asian Continental Ancestry Group
;
Cross-Sectional Studies
;
Education
;
Electronic Mail
;
Emergencies
;
Emergency Service, Hospital
;
Epidemiology
;
Humans
;
Physician Executives
;
Taiwan
;
Thailand
;
Trauma Centers
6.Use of Imaging and Biopsy in Prostate Cancer Diagnosis:A Survey From the Asian Prostate Imaging Working Group
Li-Jen WANG ; Masahiro JINZAKI ; Cher Heng TAN ; Young Taik OH ; Hiroshi SHINMOTO ; Chau Hung LEE ; Nayana U. PATEL ; Silvia D. CHANG ; Antonio C. WESTPHALEN ; Chan Kyo KIM
Korean Journal of Radiology 2023;24(11):1102-1113
Objective:
To elucidate the use of radiological studies, including nuclear medicine, and biopsy for the diagnosis and staging of prostate cancer (PCA) in clinical practice and understand the current status of PCA in Asian countries via an international survey.
Materials and Methods:
The Asian Prostate Imaging Working Group designed a survey questionnaire with four domains focused on prostate magnetic resonance imaging (MRI), other prostate imaging, prostate biopsy, and PCA backgrounds. The questionnaire was sent to 111 members of professional affiliations in Korea, Japan, Singapore, and Taiwan who were representatives of their working hospitals, and their responses were analyzed.
Results:
This survey had a response rate of 97.3% (108/111). The rates of using 3T scanners, antispasmodic agents, laxative drugs, and prostate imaging-reporting and data system reporting for prostate MRI were 21.6%−78.9%, 22.2%−84.2%, 2.3%−26.3%, and 59.5%−100%, respectively. Respondents reported using the highest b-values of 800−2000 sec/mm2 and fields of view of 9−30 cm. The prostate MRI examinations per month ranged from 1 to 600, and they were most commonly indicated for biopsy-naïve patients suspected of PCA in Japan and Singapore and staging of proven PCA in Korea and Taiwan.The most commonly used radiotracers for prostate positron emission tomography are prostate-specific membrane antigen in Singapore and fluorodeoxyglucose in three other countries. The most common timing for prostate MRI was before biopsy (29.9%). Prostate-targeted biopsies were performed in 63.8% of hospitals, usually by MRI-ultrasound fusion approach. The most common presentation was localized PCA in all four countries, and it was usually treated with radical prostatectomy.
Conclusion
This survey showed the diverse technical details and the availability of imaging and biopsy in the evaluation of PCA. This suggests the need for an educational program for Asian radiologists to promote standardized evidence-based imaging approaches for the diagnosis and staging of PCA.
7.Overview of Legal Measures for Managing Workplace COVID-19 Infection Risk in Several Asia-Pacific Countries
Miller DEREK ; Feng-Jen TSAI ; Jiwon KIM ; Mila TEJAMAYA ; Vilandi PUTRI ; Go MUTO ; Alex REGINALD ; Wantanee PHANPRASIT ; Nelia GRANADILLOS ; Marina Bt Zainal FARID ; Carmela Q. CAPULE ; Yu-Wen LIN ; Jihoon PARK ; Ruey-Yu CHEN ; Kyong Hui LEE ; Jeongim PARK ; Haruo HASHIMOTO ; Chungsik YOON ; Chantana PADUNGTOD ; Dong-Uk PARK
Safety and Health at Work 2021;12(4):530-535
Background:
Despite the lack of official COVID-19 statistics, various workplaces and occupations have been at the center of COVID-19 outbreaks. We aimed to compare legal measures and governance established for managing COVID-19 infection risks at workplaces in nine Asia and Pacific countries and to recommend key administrative measures.
Methods:
We collected information on legal measures and governance from both general citizens and workers regarding infection risks such as COVID-19 from industrial hygiene professionals in nine countries (Indonesia, India, Japan, Malaysia, New Zealand, Republic of the Philippines, Republic of Korea, Taiwan, and Thailand) using a structured questionnaire.
Results:
A governmental body overseeing public health and welfare was in charge of containing the spread and occurrence of infectious diseases under an infectious disease control and prevention act or another special act, although the name of the pertinent organizations and legislation vary among countries. Unlike in the case of other traditional hazards, there have been no specific articles or clauses describing the means of mitigating virus risk in the workplace that are legally required of employers, making it difficult to define the responsibilities of the employer. Each country maintains own legal systems regarding access to the duration, administration, and financing of paid sick leave. Many workers may not have access to paid sick leave even if it is legally guaranteed.
Conclusion
Specific legal measures to manage infectious disease risks, such as providing proper personal protective equipment, education, engineering control measures, and paid sick leave are recommended to be stipulated in Industrial safety and health-related acts.
8.Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma
Kelly M MAHURON ; Kevin M SULLIVAN ; Matthew C HERNANDEZ ; Yi-Jen CHEN ; Joseph CHAO ; Laleh G MELSTROM ; I. Benjamin PAZ ; Jae Yul KIM ; Rifat MANNAN ; James L. LIN ; Yuman FONG ; Yanghee WOO
Journal of Gastric Cancer 2024;24(3):267-279
Purpose:
The optimal treatment for gastroesophageal junction adenocarcinoma (GEJA) remains controversial. We evaluated the treatment patterns and outcomes of patients with locally advanced GEJA according to the histological type.
Materials and Methods:
We conducted a single-institution retrospective cohort study of patients with locally advanced GEJA who underwent curative-intent surgical resection between 2010 and 2020. Perioperative therapies as well as clinicopathologic, surgical, and survival data were collected. The results of endoscopy and histopathological examinations were assessed for Siewert and Lauren classifications.
Results:
Among the 58 patients included in this study, 44 (76%) were clinical stage III, and all received neoadjuvant therapy (72% chemoradiation, 41% chemotherapy, 14% both chemoradiation and chemotherapy). Tumor locations were evenly distributed by Siewert Classification (33% Siewert-I, 40% Siewert-II, and 28% Siewert-III). Esophagogastrectomy (EG) was performed for 47 (81%) patients and total gastrectomy (TG) for 11 (19%) patients.All TG patients received D2 lymphadenectomy compared to 10 (21%) EG patients.Histopathological examination showed the presence of 64% intestinal-type and 36% diffuse-type histology. The frequencies of diffuse-type histology were similar among Siewert groups (37% Siewert-I, 36% Siewert-II, and 33% Siewert-III). Regardless of Siewert type and compared to intestinal-type, diffuse histology was associated with increased intraabdominal recurrence rates (P=0.03) and decreased overall survival (hazard ratio, 2.33; P=0.02). With a median follow-up of 31.2 months, 29 (50%) patients had a recurrence, and the median overall survival was 50.5 months.
Conclusions
Present in equal proportions among Siewert types of esophageal and gastric cancer, a diffuse-type histology was associated with high intraabdominal recurrence rates and poor survival. Histopathological evaluation should be considered in addition to anatomic location in the determination of multimodal GEJA treatment strategies.
9.Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma
Kelly M MAHURON ; Kevin M SULLIVAN ; Matthew C HERNANDEZ ; Yi-Jen CHEN ; Joseph CHAO ; Laleh G MELSTROM ; I. Benjamin PAZ ; Jae Yul KIM ; Rifat MANNAN ; James L. LIN ; Yuman FONG ; Yanghee WOO
Journal of Gastric Cancer 2024;24(3):267-279
Purpose:
The optimal treatment for gastroesophageal junction adenocarcinoma (GEJA) remains controversial. We evaluated the treatment patterns and outcomes of patients with locally advanced GEJA according to the histological type.
Materials and Methods:
We conducted a single-institution retrospective cohort study of patients with locally advanced GEJA who underwent curative-intent surgical resection between 2010 and 2020. Perioperative therapies as well as clinicopathologic, surgical, and survival data were collected. The results of endoscopy and histopathological examinations were assessed for Siewert and Lauren classifications.
Results:
Among the 58 patients included in this study, 44 (76%) were clinical stage III, and all received neoadjuvant therapy (72% chemoradiation, 41% chemotherapy, 14% both chemoradiation and chemotherapy). Tumor locations were evenly distributed by Siewert Classification (33% Siewert-I, 40% Siewert-II, and 28% Siewert-III). Esophagogastrectomy (EG) was performed for 47 (81%) patients and total gastrectomy (TG) for 11 (19%) patients.All TG patients received D2 lymphadenectomy compared to 10 (21%) EG patients.Histopathological examination showed the presence of 64% intestinal-type and 36% diffuse-type histology. The frequencies of diffuse-type histology were similar among Siewert groups (37% Siewert-I, 36% Siewert-II, and 33% Siewert-III). Regardless of Siewert type and compared to intestinal-type, diffuse histology was associated with increased intraabdominal recurrence rates (P=0.03) and decreased overall survival (hazard ratio, 2.33; P=0.02). With a median follow-up of 31.2 months, 29 (50%) patients had a recurrence, and the median overall survival was 50.5 months.
Conclusions
Present in equal proportions among Siewert types of esophageal and gastric cancer, a diffuse-type histology was associated with high intraabdominal recurrence rates and poor survival. Histopathological evaluation should be considered in addition to anatomic location in the determination of multimodal GEJA treatment strategies.
10.Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma
Kelly M MAHURON ; Kevin M SULLIVAN ; Matthew C HERNANDEZ ; Yi-Jen CHEN ; Joseph CHAO ; Laleh G MELSTROM ; I. Benjamin PAZ ; Jae Yul KIM ; Rifat MANNAN ; James L. LIN ; Yuman FONG ; Yanghee WOO
Journal of Gastric Cancer 2024;24(3):267-279
Purpose:
The optimal treatment for gastroesophageal junction adenocarcinoma (GEJA) remains controversial. We evaluated the treatment patterns and outcomes of patients with locally advanced GEJA according to the histological type.
Materials and Methods:
We conducted a single-institution retrospective cohort study of patients with locally advanced GEJA who underwent curative-intent surgical resection between 2010 and 2020. Perioperative therapies as well as clinicopathologic, surgical, and survival data were collected. The results of endoscopy and histopathological examinations were assessed for Siewert and Lauren classifications.
Results:
Among the 58 patients included in this study, 44 (76%) were clinical stage III, and all received neoadjuvant therapy (72% chemoradiation, 41% chemotherapy, 14% both chemoradiation and chemotherapy). Tumor locations were evenly distributed by Siewert Classification (33% Siewert-I, 40% Siewert-II, and 28% Siewert-III). Esophagogastrectomy (EG) was performed for 47 (81%) patients and total gastrectomy (TG) for 11 (19%) patients.All TG patients received D2 lymphadenectomy compared to 10 (21%) EG patients.Histopathological examination showed the presence of 64% intestinal-type and 36% diffuse-type histology. The frequencies of diffuse-type histology were similar among Siewert groups (37% Siewert-I, 36% Siewert-II, and 33% Siewert-III). Regardless of Siewert type and compared to intestinal-type, diffuse histology was associated with increased intraabdominal recurrence rates (P=0.03) and decreased overall survival (hazard ratio, 2.33; P=0.02). With a median follow-up of 31.2 months, 29 (50%) patients had a recurrence, and the median overall survival was 50.5 months.
Conclusions
Present in equal proportions among Siewert types of esophageal and gastric cancer, a diffuse-type histology was associated with high intraabdominal recurrence rates and poor survival. Histopathological evaluation should be considered in addition to anatomic location in the determination of multimodal GEJA treatment strategies.